‹ ›
MYP_030052
← PREVIOUS NEXT → BACK
Basic Information
Unnamed
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
38 amino acids
C196H311N57O62
Standard
Sequence
TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL
Physicochemical Analysis
4457.91 Da
4.64
-3.58
-3.79
-0.0943
-0.64
0.62
-0.15
60.58
95.53
0.0789
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1976.67
-16.62
69.0
59.0
151.0
315.0
5.0
41.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0213131 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV fusion inhibitor
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1
Rat plasma, human plasma: The half-life is 4.2 h
PaperSchneider EL, Ashley GW, Dillen L, Stoops B, Austin NE, Malcolm BA, Santi DV. Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology. Eur J Pharm Biopharm Eur J Pharm Biopharm. 2015 Jun;93:254-9. PMID:25900863 https://pubmed.ncbi.nlm.nih.gov/25900863/ PMID25900863 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/25900863/
RECORD: Rec_0217357 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HIV fusion inhibitor
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Conjugated with PEG(40KDa) through Lys-30
Bio-Activity Profile
Antimicrobial Antiviral
HIV-3
Rat plasma, human plasma: The half-life is 150 h both in rat plasma and human plasma
PaperSchneider EL, Ashley GW, Dillen L, Stoops B, Austin NE, Malcolm BA, Santi DV. Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology. Eur J Pharm Biopharm Eur J Pharm Biopharm. 2015 Jun;93:254-9. PMID:25900863 https://pubmed.ncbi.nlm.nih.gov/25900863/ PMID25900863 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/25900863/
RECORD: Rec_0231272 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Conjugated with PEG(40KDa) throµgh Lys-30
Bio-Activity Profile
Antiviral Anti-HIV
LC-MS/MS
Intravenously administered to Sprague–Dawley rats, in vivo; 122400 s
PMID25900863 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/25900863/
RECORD: Rec_0262021 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Conjugated with ClPhSO2 conjugate throµgh Lys-30
Bio-Activity Profile
Antiviral Anti-HIV
LC-MS/MS
Intravenously administered to Sprague–Dawley rats, in vivo; 540000 s
PMID25900863 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/25900863/
RECORD: Rec_0320255 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antiviral
Evidence URLhttps://patents.google.com/patent/US20100261876A1/en PatentUS 2010/0261876 A1
FIRST PREV 1 2 3 NEXT LAST
Showing 5 records on this page · Page 2 of 3